Fluvastatin

Research use only, not for human use.

Fluvastatin (XU-62320) is a potent and competitive HMG-CoA reductase inhibitor (IC50: 8 nM) that inhibits oxidative stress in vascular smooth muscle cells through an Nrf2-dependent pathway, and is used for the reduction of plasma cholesterol levels and the prevention of cardiovascular disease.

Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

Fluvastatin (XU 62-320 free acid) is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin (XU 62320), HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin (XU 62320) is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

——

——

Others

Other Targets

HMG-CoA Reductase

——

——

93957-54-1

411.47

C24H26FNO4

>98% (HPLC)

In Vitro:?DMSO : 5 mg/mL (12.15 mM; Ultrasonic (<60°C)

C(=C/[C@@H](C[C@@H](CC(O)=O)O)O)\C1=C(C=2C(N1C(C)C)=CC=CC2)C3=CC=C(F)C=C3

——

(-20℃)

With Ice Pack

≥ 2 years